<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01985698</url>
  </required_header>
  <id_info>
    <org_study_id>RLAPR</org_study_id>
    <nct_id>NCT01985698</nct_id>
  </id_info>
  <brief_title>A Trial of Robotic-assisted Versus Laparoscopic Abdominoperineal Resection for Treating Low Rectal Cancer</brief_title>
  <acronym>RLAPR</acronym>
  <official_title>A Single-centre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Abdominoperineal Resection for the Curative Treatment of Low Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators assessed the difference in efficacy and safety among&#xD;
      robotic-assisted versus laparoscopic abdominoperineal resection for patients with low rectal&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be eligible for inclusion if their primary tumors is low rectal cancer.&#xD;
&#xD;
      Eligible patients will be randomly assigned to robotic-assisted (arm A) versus laparoscopic&#xD;
      (arm B) abdominoperineal resection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>30 days post operatively</time_frame>
    <description>postoperative complications related to operation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>operative mortality</measure>
    <time_frame>30 days post operatively</time_frame>
    <description>death occurred 30 days after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>disease-free survival rate at 3 years after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 and 5 years</time_frame>
    <description>overall survival rate at 3 and 5 years after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>locoregional recurrence rate</measure>
    <time_frame>3 and 5 years</time_frame>
    <description>local recurrence rate at 3 and 5 years after operation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>operative time</measure>
    <time_frame>Day 1</time_frame>
    <description>Time from cutting the skin to suturing the incision during the surgery, recorded in minute</description>
  </other_outcome>
  <other_outcome>
    <measure>rate of conversion to open surgery</measure>
    <time_frame>Day 1</time_frame>
    <description>The rate of patients actually receiving open surgery in robotic or laparoscopic surgery groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>estimated blood loss</measure>
    <time_frame>Day 1</time_frame>
    <description>Blood loss will be measured according to the suction and the weight of wet gauze, and then minus the irrigation.</description>
  </other_outcome>
  <other_outcome>
    <measure>circumferential resection margin</measure>
    <time_frame>10 days post operatively</time_frame>
    <description>The circumferential margin will be reported as &quot;positive&quot; or &quot;negative&quot; to define whether tumor is radically resected. It will be reported according to the post-operative pathology. Details are based on NCCN and Chinese guidelines for colorectal cancer.</description>
  </other_outcome>
  <other_outcome>
    <measure>proximal/distal resection margin</measure>
    <time_frame>10 days post operatively</time_frame>
    <description>The proximal/distal resection margin will be reported as &quot;positive&quot; or &quot;negative&quot; to define whether tumor is radically resected. It will be reported according to the post-operative pathology. Details are based on NCCN and Chinese guidelines for colorectal cancer.</description>
  </other_outcome>
  <other_outcome>
    <measure>number of retrieved lymph nodes</measure>
    <time_frame>10 days post operatively</time_frame>
    <description>It will be reported according to the post-operative pathology.</description>
  </other_outcome>
  <other_outcome>
    <measure>postoperative hospital stay</measure>
    <time_frame>30 days post operatively</time_frame>
    <description>The postoperative hospital stay is defined as the number of date from the first day after operation to discharge.</description>
  </other_outcome>
  <other_outcome>
    <measure>self reported bladder function</measure>
    <time_frame>at postoperative 3, 6 and 1 2 months</time_frame>
    <description>This section is assessed using a self-rating scale &quot;International prostate symptom score&quot; (IPSS)</description>
  </other_outcome>
  <other_outcome>
    <measure>self reported sexual function for male patients</measure>
    <time_frame>at postoperative 3, 6 and 1 2 months</time_frame>
    <description>This section is assessed using a self-rating scale &quot;International Index of Erectile Function&quot; (IIEF-5).</description>
  </other_outcome>
  <other_outcome>
    <measure>self reported sexual function for female patients</measure>
    <time_frame>at postoperative 3, 6 and 1 2 months</time_frame>
    <description>This section is assessed using a self-rating scale &quot;Female Sexual Function Index&quot; (FSFI).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">347</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Robotic-assisted resection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with low rectal cancer receiving robotic-assisted abdominoperineal resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with low rectal cancer receiving laparoscopic abdominoperineal resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robotic-assisted resection.</intervention_name>
    <description>Robotic-assisted abdominoperineal resection.</description>
    <arm_group_label>Robotic-assisted resection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic resection</intervention_name>
    <description>Laparoscopic abdominoperineal resection</description>
    <arm_group_label>Laparoscopic resection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven rectal adenocarcinoma&#xD;
&#xD;
          -  Inferior edge of the tumor located within 5 cm from the anal verge as determined by&#xD;
             colonoscopy withdrawing and digital rectal examination&#xD;
&#xD;
          -  No evidence of distant metastases (including pelvis, peritoneum, liver, lung, brain,&#xD;
             bone, distant lymph node, etc) according to ultrasound, CT, PET-CT, etc&#xD;
&#xD;
          -  Tumor assessed as cT1-T3 or ycT1-T3 after preoperative neoadjuvant chemoradiotherapy&#xD;
             by pelvic MRI&#xD;
&#xD;
          -  No other malignancies in medical history except adequately treated basocellular&#xD;
             carcinoma of the skin or in situ carcinoma of the cervix uteri&#xD;
&#xD;
          -  Suitable for both robot-assisted and laparoscopic surgery&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) class I - III&#xD;
&#xD;
          -  No other preoperative treatment except neoadjuvant chemoradiotherapy&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tumors assessed as cT1N0 and suitable for local excision&#xD;
&#xD;
          -  Signs of acute intestinal obstruction, bleeding or perforation needing emergency&#xD;
             surgery&#xD;
&#xD;
          -  More than one colorectal tumor&#xD;
&#xD;
          -  Familial Adenomatosis Polyposis, Lynch Syndrome, acute inflammatory bowel disease&#xD;
&#xD;
          -  Schedules need for other synchronous colon surgery&#xD;
&#xD;
          -  Absolute contraindications to general anesthesia or prolonged pneumoperitoneum (ASA&#xD;
             class &gt; III)&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Patients and/or family members can not understand and accept this study&#xD;
&#xD;
          -  Patients received chemoradiotherapy or other anti-tumor therapy before surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianmin Xu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 9, 2013</study_first_submitted>
  <study_first_submitted_qc>November 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <last_update_submitted>March 6, 2021</last_update_submitted>
  <last_update_submitted_qc>March 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xu jianmin</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Low rectal cancer</keyword>
  <keyword>Robotic</keyword>
  <keyword>Laparoscopic</keyword>
  <keyword>Abdominoperineal resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

